Market by Product, Application, Technology, End-user and Geography | Forecast 2019-2028
A Triton Market Research report has determined that the molecular point of care diagnostics market in the Middle East and Africa is set to surge at CAGR of 13.75% during the projected period 2019-2028.
We provide additional customization based on your specific requirements. Request For Customization
The countries scrutinized in the Middle East and Africa market are:
•          Turkey
•          Saudi Arabia
•          United Arab Emirates
•          South Africa
•          Rest of Middle East & Africa
Turkey has taken several initiatives to re-establish the crumbling healthcare system in the past few years. For instance, in order to avoid the problem of overcrowding in the hospitals run by the Social Security Fund, they were merged with the hospital run by the Health Ministry. Also, city hospitals, especially in the suburbs, are the latest development initiative to drive the modernization of Turkey's health sector.
The government aims to enhance the country's health standards by increasing the average hospital bed capacity. The country has been identified as the fastest rising infection rates across the world, partially owing to the increased testing capacity. Turkey is among the top 10 countries in the world, with the maximum number of COVID-19 tests carried out. These factors are likely to instigate the growth of the molecular point of care diagnostics market.
The Saudi Arabian healthcare system has developed rapidly in the past few years. This growth may be contributed by the country's increased wealth and the fact that healthcare quality is its high priority. Besides, free universal healthcare in the country will ensure fair access to the entire population. These factors will consequently help the market for the molecular point of diagnostics.
Mesa Biotech is a company that is engaged in designing, developing, manufacturing and marketing next-generation molecular diagnostic tests. Concerning the molecular point of care diagnostics, the company provides Accula System, which consists of a portable dock and specific test cassettes. The company also provides Accula Flu A/Flu B and the Accula RSV assay for the diagnosis of respiratory diseases.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  INCREASED GERIATRIC POPULATION REQUIRES MORE DIAGNOSTIC SERVICES
2.2.2.  OPPORTUNITIES FROM EMERGING COUNTRIES FOR THE MARKET
2.2.3.  HYBRIDIZATION OF AVAILABLE TECHNOLOGIES IS A PROMISING TREND
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1.  THREAT OF NEW ENTRANTS
2.3.2.  THREAT OF SUBSTITUTE
2.3.3.  BARGAINING POWER OF SUPPLIERS
2.3.4.  BARGAINING POWER OF BUYERS
2.3.5.  THREAT OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. MARKET DRIVERS
2.6.1.  DEMAND FOR DIAGNOSING PRESENCE OF SARS COV-2
2.6.2.  INCREASING DEMAND FOR NON-INVASIVE DIAGNOSIS
2.6.3.  RISE IN THE NUMBER OF DISEASES
2.7. MARKET RESTRAINTS
2.7.1.  HIGH CAPITAL REQUIREMENT
2.8. MARKET OPPORTUNITIES
2.8.1.  SPENDING ON RESEARCH & DEVELOPMENT
2.8.2.  INNOVATIONS IN THE MARKET
2.9. MARKET CHALLENGES
2.9.1.  LACK OF HIGH COMPLEXITY TESTING CENTERS
3. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK – BY PRODUCT
3.1. ASSAYS
3.2. INSTRUMENTS
3.3. SOFTWARE
4. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY APPLICATION
4.1. INFECTIOUS DISEASE
4.1.1.  RESPIRATORY
4.1.2.  HOSPITAL-ACQUIRED INFECTIONS
4.1.3.  SEXUALLY-TRANSMITED INFECTIONS
4.1.4.  GASTROINTESTINAL INFECTIONS
4.2. ONCOLOGY
4.3. PRENATAL
4.4. OTHERS
5. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY TECHNOLOGY
5.1. POLYMERASE CHAIN REACTION
5.1.1.  REAL-TIME PCR (Q-PCR)
5.1.2.  DIGITAL PCR (D-PCR)
5.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
5.3. OTHER
6. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY END-USER
6.1. HOSPITAL
6.2. CLINICS
6.3. DIAGNOSTIC CENTERS
6.4. OTHERS
7. MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET – REGIONAL OUTLOOK
7.1. UNITED ARAB EMIRATES
7.2. TURKEY
7.3. SAUDI ARABIA
7.4. SOUTH AFRICA
7.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT
8.2. ABACUS DIAGNOSTICA
8.3. BIOMERIEUX SA
8.4. BIOCARTIS
8.5. DANAHER
8.6. DIASORIN SPA
8.7. BIO-RAD LABORATORIES INC
8.8. F HOFFMANN-LA ROCHE LTD
8.9. LUMINEX CORPORATION
8.10. HOLOGIC INC
8.11. MESA BIOTECH
8.12. SPARTAN BIOSCIENCES INC
8.13. QUANTUMDX GROUP LTD
8.14. QUIDEL CORPORATION
8.15. QIAGEN
9. METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY
TABLE 1: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 5: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 6: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 7: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 8: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 9: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 10: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: COST COMPARISON BETWEEN LABORATORY, IMMUNOASSAY AND MOLECULAR POC DIAGNOSTIC TESTS
FIGURE 3: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)
FIGURE 4: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)
FIGURE 5: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)
FIGURE 6: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
FIGURE 7: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL-ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY-TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTROINTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
FIGURE 15: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL-TIME PCR (Q-PCR), 2019-2028 (IN $ MILLION)
FIGURE 16: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR (D-PCR), 2019-2028 (IN $ MILLION)
FIGURE 17: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 18: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)
FIGURE 19: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL, 2019-2028 (IN $ MILLION)
FIGURE 20: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)
FIGURE 21: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTERS, 2019-2028 (IN $ MILLION)
FIGURE 22: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 23: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2018 & 2028 (IN %)
FIGURE 24: UNITED ARAB EMIRATES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 25: TURKEY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: SAUDI ARABIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: SOUTH AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: REST OF MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)